Generic placeholder image

Current Diabetes Reviews


ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Case Report

A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet

Author(s): Brenda Dorcely*, Juliana Nitis, Arthur Schwartzbard, Jonathan D. Newman, Ira J. Goldberg and Melissa Sum

Volume 17, Issue 2, 2021

Published on: 16 March, 2020

Page: [243 - 246] Pages: 4

DOI: 10.2174/1573399816666200316112709

Price: $65


Introduction: Sodium-glucose cotransporter-2 [SGLT2] inhibitors reduce cardiovascular events and mortality in patients with diabetes, particularly patients with established cardiovascular disease. Euglycemic diabetic ketoacidosis [euDKA], a complication of SGLT2 therapy, can be exacerbated by a low carbohydrate diet.

Case Report: A 61-year-old man with a history of type 2 diabetes, taking an SGLT2 inhibitor empagliflozin 10 mg orally daily, presented to the emergency room with a 2-day history of nausea and chest pain. A week prior to presentation, he had started a ketogenic diet. He was initially admitted with a diagnosis of acute coronary syndrome. On initial assessment in the emergency room, his cardiac enzymes were normal and there were no ischemic changes in his ECG. As there was concern for unstable angina, he underwent cardiac catheterization, which showed a known total occlusion with collaterals and arteries with a non-obstructive disease without any evidence of acute plaque rupture. His baseline laboratory assessments revealed an elevated anion gap of 17, increased urinary and plasma ketones, and metabolic acidosis. His plasma glucose level was 84 mg/dL. The diagnosis of euDKA was made, and treatment with intravenous fluids and insulin was initiated. His chest pain and nausea subsequently resolved.

Conclusion: We present a case of euDKA triggered by a ketogenic diet while on SGLT2 inhibitor therapy presenting as chest pain. The recognition of euDKA is important in the context of increased SGLT2 use for the management of cardiovascular risk for patients with diabetes.

Keywords: Acute coronary syndrome, chest pain, coronary artery disease, ketoacidosis, diabetes mellitus type 2, sodiumglucose transporter 2 inhibitors.

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-28.
[] [PMID: 26378978]
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7): 644-57.
[] [PMID: 28605608]
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42(Suppl. 1): S103-23.
[] [PMID: 30559236]
Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 2015; 38(9): 1687-93.
[] [PMID: 26078479]
Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 2017; 33(5)
[] [PMID: 28099783]
Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr 2013; 67(8): 789-96.
[] [PMID: 23801097]
Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 2015; 6(5): 587-90.
[] [PMID: 26417418]
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42(Suppl. 1): S90-S102.
[] [PMID: 30559235]
Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res 2018; 122(10): 1439-59.
[] [PMID: 29748368]
Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ. The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review. J Am Coll Cardiol 2018; 72(15): 1856-69.
[] [PMID: 30286929]
Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. J Am Coll Cardiol 2011; 58(24): 2533-40.
[] [PMID: 22079127]
Mohamad NAR, Cheah PK. Chest pain in emergency department: A diagnosis of diabetic ketoacidosis must be ruled out. Int J Case Rep Imag 2010; 1(3): 6-9.
Dai Z, Nishihata Y, Kawamatsu N, et al. Cardiac arrest from acute myocardial infarction complicated with sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis. J Cardiol Cases 2016; 15(2): 56-60.
[] [PMID: 30546697]
Batra AS, Acherman RJ, Wong P, Silka MJ. Acute myocardial infarction in a 12-year-old as a complication of hyperosmolar diabetic ketoacidosis. Pediatr Crit Care Med 2002; 3(2): 194-6.
[] [PMID: 12780995]
Carl GF, Hoffman WH, Passmore GG, et al. Diabetic ketoacidosis promotes a prothrombotic state. Endocr Res 2003; 29(1): 73-82.
[] [PMID: 12665320]
Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355(9206): 773-8.
[] [PMID: 10711923]
Kurien VA, Oliver MF. Serum-free-fatty-acids after acute myocardial infarction and cerebral vascular occlusion. Lancet 1966; 2(7455): 122-7.
[] [PMID: 4161376]
Schrieks IC, Nozza A, Stähli BE, et al. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care 2018; 41(8): 1792-800.
[] [PMID: 29903845]
Wilding J, Fernando K, Milne N, et al. SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. Diabetes Ther 2018; 9(5): 1757-73.
[] [PMID: 30039249]
Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab 2019; 21(S2)(Suppl. 2): 34-42.
[] [PMID: 31081590]
Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on The Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocr Pract 2016; 22(6): 753-62.
[] [PMID: 27082665]
Sood M, Simon BF, Ryan K, Zebrower M. Euglycemic Diabetic Ketoacidosis with Sglt2 Inhibitor Use in a Patient on the Atkins Diet: A Unique Presentation of a Known Side Effect. AACE Clin Case Rep 2018; 4: e104-7.
Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015; 100(8): 2849-52.
[] [PMID: 26086329]
Saponaro C, Pattou F, Bonner C. SGLT2 inhibition and glucagon secretion in humans. Diabetes Metab 2018; 44(5): 383-5.
[] [PMID: 30017776]
Yabe D, Iwasaki M, Kuwata H, et al. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab 2017; 19(5): 739-43.
[] [PMID: 27990776]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy